GEORGIA BOARD OF PHARMACY
Board Meeting
2 Peachtree Street, NW, 36th Floor
Atlanta, GA 30303
March 19, 2014
9:00 a.m.

The following Board members were present:
Al McConnell, Chairperson
Laird Miller, Vice-Chairperson
Jim Bracewell
Mike Faulk
Chris Jones
Tony Moye
Bill Prather
Bob Warnock

Staff present:
Tanja Battle, Executive Director
Rick Allen, GDNA
Janet Wray, Senior Assistant Attorney General
Brandi Howell, Business Operations Specialist

Visitors:
LaChandra Smith
Keith Ahlfinger
Jim Bartling
Rajib U. Khan
Fran Cullen
Pam Cox
Mark Ranney
Jimmy England, Walgreens
Melvin Smith, CVS
Scott Biddulph, Target
Mike Poblet, Publix
Ana Smith, Publix
Yi Huang
Helen Sloat, Kaiser & Hemophilia of GA
Hal Henderson, Omnicare
Stephanie Kozol
Jon Martin, Gayco Healthcare
Ben DiMarco, Davita Rx
John Sisto, ESI
Todd Haley, Walmart
Scott Lindsay, CAPS
Michael Weiss, WorkingBuildings
Kurt Last, WorkingBuildings
Larry Lord, WorkingBuildings
Tiffany Ollanove, WorkingBuildings
Monica Bell, WorkingBuildings

Chairperson McConnell established that a quorum was present and called the meeting to order at 9:02 a.m.

Chris Jones made a motion and Bob Warnock seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h)(2) and §43-1-2(k) to deliberate and to receive information on applications, investigative reports and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Al McConnell, Laird Miller, Jim Bracewell, Mike Faulk, Chris Jones, Tony Moye, Bill Prather and Bob Warnock.

Executive Session

Appearance

- L.D.S.

Attorney General's Report – Janet Wray

Ms. Wray presented the following consent orders for acceptance:

- C.E.C.
- C.V.S.
- C.V.S.
- K.D.
- M.I.
- M.I.
- M.I.
- C.A.P.
- P.
- S.M.S.I.
- R.E.J.

Ms. Wray presented the following Voluntary Surrender for acceptance:

- A.D.S.

Ms. Wray discussed the following cases:

- M.P.L.
- T.C.
- D.K.

Appearances

- K.W.A.
- R.U.K.
- P.A.C.

No votes were taken in Executive Session. Chairperson McConnell declared the meeting back in Open Session.

Public Hearing

Chairperson McConnell called the Public Hearing to order at 11:52 a.m.

Rule 480-10-.21 Purchase or Receipt of Drugs by a Pharmacy

No comments or written responses were received.

Rule 480-16-.08 Purchase or Receipt of Drugs by a Pharmacy

No comments or written responses were received.

The hearing was adjourned at 11:53 a.m.

Bill Prather made a motion to adopt Rule 480-10-.21 Purchase or Receipt of Drugs by a Pharmacy and Rule 480-16-.08 Purchase or Receipt of Drugs by a Pharmacy. Bob Warnock seconded and the Board voted unanimously in favor of the motion.

Open Session

Approval of Minutes
Laird Miller made a motion to approve the Public Session minutes for the February 19, 2014 meeting. Chris Jones seconded and the Board voted unanimously in favor of the motion.

Chris Jones made a motion to approve the Executive Session minutes for the February 19, 2014 meeting. Laird Miller seconded and the Board voted unanimously in favor of the motion.

Ratifications
Chris Jones made a motion to ratify the list of issued licenses. Laird Miller seconded and the Board voted unanimously in favor of the motion.

Petition for Rule Waiver – Vensun Pharmaceuticals, Inc.
Bill Prather made a motion to deny the rule waiver petition. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

Petition for Rule Waiver – Oladipo Olusoji Adebisi
Chris Jones made a motion to deny the rule waiver petition. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

Correspondence from Robert Mauro, Silvergate Pharmaceuticals, Inc.
The Board viewed correspondence that was for informational purposes only.

Correspondence from Patricia P. Vincent
The Board considered this correspondence and directed staff to respond to Ms. Vincent by referring her to section (l) of Board Rule 480-37-.03 Minimum Requirements.

Correspondence from Barclay Wiseman
The Board considered this correspondence from Mr. Wiseman concerning intern requirements. The Board directed staff to respond to Mr. Wiseman by notifying him that the Board is taking his correspondence under advisement.

Correspondence from Roy B. Braddy, RPH015300
The Board considered this correspondence from Mr. Braddy requesting the Board terminate his probation. The Board recommended approving his request.

Correspondence from Jennifer Mantegani-Paul, ProTrainings, LLC
The Board considered this correspondence from Ms. Mantegani-Paul requesting the Board approve ProTrainings as a provider for CPR and First Aid training for Pharmacy professionals. The Board directed staff to respond to Ms. Mantegani-Paul by stating that the Board does not require CPR training for Pharmacy professionals.

Georgia Drugs and Narcotics Agency – Rick Allen
No report.

Attorney General's Report – Janet Wray
No report.

Miscellaneous

Letter from Michael J. Melroy, BCPS: The Board considered this correspondence and directed staff to respond by stating that the deadline to submit supporting documents to the Board office will be May 15th.

Executive Director's Report – Tanja Battle

Organizational Chart: Ms. Battle discussed an organizational chart that was provided to the Board. Ms. Battle stated that certain positions are assigned to a specific Board; however, at this time we are cross utilizing all staff during the renewal period.

Budget: Ms. Battle reported on the budget.

Correspondence from Daisy Cameron, Lookout Mountain Community Services 1 Pharmacy: Ms. Battle shared correspondence received from Ms. Cameron regarding whether or not they need to initial the hardcopy sticker that is placed on the back of each prescription if their daily report prints each prescription that is filled that day and each pharmacist on duty that day signs the report. The Board recommended staff respond to Ms. Cameron by stating that it is not required in the current pharmacy rules and regulations.

Miscellaneous

Tony Moye made a motion to repost the following rules:

480-38-.01 Scope and Application of These Rules.
The following Rules govern procedure in "contested cases" as that term is defined in the Georgia Administrative Procedure Act (O.C.G.A. 50-13-2(2)) and which are conducted before the Board of Pharmacy. Additional Rules in subsequent chapters may also apply.

480-38-.02 Docket
(1) The Executive Director shall keep a book known as a docket, which shall be arranged by a sequential numbering system for each case or other matter and shall show for each case of matter, as permitted by law, all proceedings, actions and filings.
(2) The Executive Director shall keep a docket index by both docket number and alphabetical list of the names of the respondents in all proceedings.

480-38-.03 Office Hours
The offices of the Board of Pharmacy shall be open from 8:00 a.m. to 5:00 p.m. each weekday, except State legal holidays.

480-38-.04 Communications
All communications, including correspondence, motions, and pleadings, shall be filed with the Executive Director, Board of Pharmacy, 2 Peachtree Street, 36th Floor, Atlanta, GA 30303. Copies shall be furnished to all parties of record, including the attorney representing the State. An original of all correspondence, motions, and pleadings shall be filed with the Executive Director and shall comply in all respects with Rule 480-41-.04.

480-38-.05 Date of Filing.
All communications, correspondence, motions and pleadings in any proceedings shall be deemed to be filed or received on the date on which they are actually received by the Executive Director.

480-38-.06 Computation of Time

Computation of any period of time referred to in these rules shall begin with the first day following that on which the act which initiates such period of time occurs. When the last day of the period so computed is a day on which the office of the Board of Pharmacy is closed, the period shall run until the end of the following business day. When such period of time, with the intervening Saturdays, Sundays and legal holidays counted, is seven (7) days or less, the said Saturdays, Sundays and legal holidays shall be excluded from the computation; or otherwise such days shall be included in the computation.

480-38-.07 Extension of Times

It shall be within the discretion of the Board or its designee to extend, for good cause shown, any time limit prescribed or allowed by these rules. All requests for an extension should be made by a motion in accordance with 480-40-.01 and shall indicate therein whether all parties concur. The Board or its designee shall notify all parties of its action upon the motion. Extension shall be granted only when the Board or its designee is satisfied that good cause has been shown and not otherwise.

480-38-.08 Signatures

Every notice, pleading, petition, motion or other document filed by a party, represented by an attorney, shall be signed by at least one attorney of record in his/her individual name. His/her address, e-mail address, telephone number, and representative capacity shall be stated. A party who is not represented by an attorney shall sign his pleading and state his address, e-mail address, and telephone number. Except when otherwise specifically provided by rule or statute, pleadings need not be verified or accompanied by affidavit. The signature of an attorney constitutes a certificate by him/her that s/he has read the pleading, and that it is not interposed for delay.

480-38-.09 Ex-parte Communication

No person not employed by the Board of Pharmacy shall communicate *ex-parte* with any member of the Board of Pharmacy involved in the decisional process with respect to the merits of a contested case. If any *ex-parte* communication is directed to any person in violation of these rules, the Board or its designee and all other parties shall be immediately informed of the substance of the communication and the circumstances of its receipt; provided, that a request for information with respect to the status of a proceeding shall not be prohibited by this section.

480-38-.10 Petition for Promulgation, Amendment, or Repeal of Rules

(1) Form of Petition. Each petition for promulgation, amendment or repeal of rules made pursuant to the Georgia Administrative Procedure Act shall be filed with the Board of Pharmacy. The petition shall be in writing and shall state:

(a) The name and address of the petitioner;

(b) The full text of the rule requested to be amended or repealed, or the full text of the rule desired to be promulgated;

(c) A statement of the reason such rule should be amended, repealed, or promulgated including a statement of all pertinent existing facts which relate to petitioner's interest in the matter;

(d) Citations of legal authority, if any, which authorize, support, or require the action requested by petition. The petition shall be verified under oath by or in proper behalf of; the petitioner.

(2) Proceeding on Petition. Upon receipt of the petition, the Board of Pharmacy shall decide upon the action to be taken. Within thirty days after receipt of the petition, the Board either shall deny the petition in writing (stating its reasons for the denial) or shall initiate rule-making or rule-changing proceedings in accordance with the Georgia Administrative Procedure Act.

480-39-.01 Initial Pleading

(1) The hearing in a contested case shall be commenced by the Board's filing of a notice of hearing directed to the respondent, or respondents.

(2) Every pleading or other paper submitted for filing in a contested case, to the extent possible, shall contain the following:
(a) A title which indicates the nature of the proceeding and the parties involved therein;
(b) The name of the Board;
(c) A short and plain statement of the nature of the pleading (e.g. Answer, Motion for Continuance, etc.);
(d) In addition, the notice of hearing shall, to the extent possible, contain the following:
1. A short and plain statement of the matters asserted or the issues involved;
2. A clear and concise statement of the laws involved;
3. A notice of the rights of the person to whom the notice of hearing is directed;
4. A statement that an answer to the matters asserted is required; and
5. Any other information required by law or deemed appropriate by the Board.

480-39-.02 Answer
The party to whom a notice of hearing is directed must file with the Board an answer within fourteen (14) days after service of the notice of hearing. All allegations contained in the notice of hearing which are not specifically admitted are deemed denied.

480-39-.03 Replies
A reply to the answer shall not be permitted and any new matters asserted in the answer shall be deemed denied.

480-39-.04 Amendments
Any party, including the Board, may amend any pleading or notice without leave until the eighth day prior to the date set for the hearing on the matter. Thereafter a party may amend his pleadings only by leave of the Board or its designee and leave shall be freely given when justice so requires. If an amendment is made to a notice of hearing, the answer to said amended notice shall be filed within seven (7) days after service of the amended notice, unless otherwise ordered by the Board or its designee.

480-40-.01 Motions: Written and Oral
(1) An application to the Board for an order to take any action or to enter any order shall be made by motion which, unless made during the hearing, shall be made in writing, shall state specifically the grounds therefor, and shall set forth the action or order sought. A copy of all written motions shall be served upon the parties in accordance with Chapter 480-42.
(2) A motion for a continuance or an extension of time shall be ruled upon by the Board or its designee forthwith. All other motions shall be ruled upon by the Board or its designee at the outset of the hearing, after an opportunity for argument by the parties; provided, however, that the Board or its designee may establish a hearing schedule and dispose of motions. The Board or its designee may request briefs in support of or in opposition to any motion.

480-40-.02 More Definite Statement
A motion for more definite statement shall be filed and ruled upon pursuant to 480-40-.01.

480-40-.03 General Procedures.
Proceedings before the Board shall be conducted as expeditiously as possible, with due regard to the rights of the parties. In contested cases before the Board of Pharmacy upon issuance of a notice of hearing, the procedures set forth in this chapter and Chapters 480-38 through Chapter 480-47 shall enable the parties to obtain relevant information needed for preparation of the case, to the extent that such disclosure is authorized by law.

480-40-.04 Witness Lists and Respondent Statements.
(1) Should a party seek a list of the names of witnesses, including experts, whom another party expects to call or may call on its behalf, the party seeking the list must communicate the request in writing (by

mail, personal service, or electronically) to the other party at least fourteen (14) days prior to the hearing. Such a request must also be filed with the Executive Director, Board of Pharmacy, 2 Peachtree Street, 36th Floor, Atlanta, GA 30303. The party of whom the information is requested shall, within a reasonable time prior to the commencement of the hearing but at least ten (10) days prior to the hearing, provide such a list to the requester.

(2) The parties may also, within a reasonable period of time prior to the hearing, exchange copies of documents and designate documents already in the possession of the other party which are intended to be introduced as evidence at the hearing. Upon request, the parties shall make available to each other for inspection, copying, testing or sampling any tangible item intended to be introduced as evidence, within a reasonable period of time prior to the hearing. Where a party seeks documents or other evidence already in the possession of the other party which are intended to be introduced as evidence at the hearing, the party seeking the documents must communicate a request for the evidence in writing (by mail, personal service, or electronically) to the other party at least fourteen (14) days prior to the hearing. Such a request must also be filed with the Executive Director, Board of Pharmacy, 2 Peachtree Street, 36th Floor, Atlanta, GA 30303. The party of whom the information is requested shall, within a reasonable time prior to the commencement of the hearing but at least ten (10) days prior to the hearing, provide such evidence to the requester or file a motion seeking an order to quash the request.

(3) If a licensee makes a general or specific written request to the Board for exculpatory, favorable, or arguably favorable evidence that is relative to pending allegations concerning the licensee, the Board must furnish the requested information, indicate that no such information exists, or refuse to furnish the information requested prior to a hearing.

(a) The Board is not required to furnish information made confidential by state or federal law, until such requested information has been determined to be exculpatory, favorable, or arguably favorable pursuant to the *in camera* procedure specified in part (b) of this subsection.

(b) Once the Board has furnished exculpatory, favorable, or arguably favorable information, has indicated that no such information exists, or has refused to furnish such information, a licensee may request a prehearing *in camera* inspection of the remainder of the investigative file by the Board or its designee. The Board or its designee shall furnish the licensee with all material that would aid in the licensee's defense that is exculpatory, favorable, or arguably favorable. The Board or its designee shall seal a copy of the entire investigative file in order to preserve it in the event of an appeal.

(4) If a party refuses to or neglects to produce documents, evidence, witness lists or statements in accordance with a request pursuant to 480-40-.04(1) or 480-40-.04(2), the Board or its designee may issue an order compelling production by motion of the requester or on its own motion. Where the party of whom information is requested has filed a motion to quash the request for production pursuant to 480-40-.01 and 480-40-.04(2), the Board or its designee may issue an order to quash the request for production upon good cause shown by the party requesting such an order. If a party subsequently refuses to or neglects to produce the requested materials in spite of an order compelling it to do so, the Board or its designee shall have the same rights and powers given the court under the Georgia Civil Practice Act. The Board or its designee may certify the facts to the Superior Court of Fulton County or any county where the offense is committed for appropriate action, including a finding of contempt. The Board or its designee shall have the power to issue writs of *fieri facias* in order to collect fines imposed for violation of a lawful order of the Board or its designee.

(5) The parties shall be required to confer either in person or by telephone, in reasonable advance of a scheduled hearing date but at least seven (7) days prior to the hearing, in a good-faith attempt to reach an agreement as to the admissibility of any documents or tangible items intended to be offered in evidence for either side. The parties may stipulate as to any matter of fact and such stipulation will satisfy a party's burden of proving the fact alleged. The parties shall be encouraged to reach pre-hearing stipulations which could facilitate adjudication of the case. The Board or its designee, upon its own motion or upon the request of either party, may schedule a pre-hearing conference to hear and rule on motions or other preliminary matters, or otherwise facilitate adjudication of the case.

480-40-.05 Pre-Hearing Discovery
Except as may be expressly authorized by these Rules or by statute, no other forms of prehearing discovery shall be authorized or permitted including, but not limited to, interrogatories and requests for production of documents and other materials.

480-41-.01 By the Board
(1) Service of the notice of hearing, initial decision and final order shall be served personally upon the licensee or applicant or served by certified mail or statutory overnight delivery, return receipt requested, to the last known address of record with the Board.
(2) All other notices, pleadings, orders, motions and other documents shall be personally upon the licensee or applicant or served by certified mail or statutory overnight delivery, return receipt requested, to the last known address of record with the Board.
(3) If such materials are served by certified mail or statutory overnight delivery and are returned marked "unclaimed" or "refused" or is otherwise undeliverable, and if the licensee or applicant cannot, after diligent effort, be located, the Executive Director or his or her designee, shall be deemed the agent of service for such licensee or applicant, and service upon the Executive Director or his or her designee shall be deemed service upon the licensee or applicant.

480-41-.02 Service On All Parties.
A copy of the answer and all other pleadings, notices, motions, briefs, memoranda and other documents filed by any party with the Executive Director shall be served upon all other parties to the proceeding, including counsel for the Board, by personal delivery or by certified mail, return receipt requested.

480-41-.03 To Party's Attorney
Service upon a party's attorney shall be deemed service upon the party.

480-41-.04 Filing of Pleading
(1) A party filing a document or other submission with the Board shall simultaneously serve a copy of the document or submission on each party of record. Service shall be by personal delivery, e-mail as an attachment, first-class mail, certified mail, or statutory overnight delivery, return receipt requested.
(2) A pleading subsequent to the Notice of Hearing shall not be entitled to filing unless accompanied by an Acknowledgement of Service from the person served, by his or her authorized agent for service, or by a certificate of service stating the date, place, and manner or service, as well as the name and address of the person(s) served.

480-42-.01 Intervention
(1) Any person desiring to intervene pursuant to O.C.G.A. § 50-13-14 shall file a motion in accordance with Rule 480-40-.01 and 480-41-.04.
(a) Such a motion can be made where a statute grants the movant an unconditional right to intervene or when representation of the movant's interest is or may be inadequate to protect that interest.
(b) Such a motion can also be made where a statute grants the person a conditional right to intervene or where the movant's claim or defense and the main action have a question of law or fact in common.
(2) The motion shall state therein the specific grounds for seeking intervention. The Board and any other parties shall have fourteen (14) days from the date of service to file a response to such request.
(3) In considering the motion, the Board or its designee shall consider whether the intervention will unduly delay or prejudice the rights of existing parties.

480-43-.01 Evidence on Hearings
Unless otherwise provided by these rules, in all hearings, the testimony of witnesses shall be taken orally before the Board or its designee and presentation of all documentary and other evidence shall be done before the Board or its designee.

480-43-.02 Evidence on Motions
When a motion is based on facts not appearing of record, the Board or its designee may hear the matter on affidavits presented by the respective parties, but the Board or its designee may direct that the matter by heard wholly or partly on oral testimony.

480-43-.03 Objections and Exceptions
Any objections and exceptions must be made on the record, and at a minimum, must make clear to the Board or its designee the action which s/he desires taken and the grounds therefor.

480-43-.04 Subpoenas.
(1) In contested cases, subpoenas shall be issued without discrimination between public and private parties. At any time after issuance of the Notice of Hearing, and prior to the scheduled date for the hearing, the parties may request the issuance of subpoenas by filing a written request with the Executive Director, in accordance with Rule 480-38-.04, with appropriate service on the opposing party or counsel. Subpoena requests shall state the name and complete address of the person to whom it is directed.
(2) Subpoenas issued pursuant to a request in accordance with Rule 480-43-.04(1) shall not be issued in blank. Every subpoena issued by the Executive Director shall state the name of the Board of Pharmacy and the title of the action, and shall command each person to whom it is directed to attend and give testimony at the hearing at a time and place therein specified, or to produce documents for examination at the hearing, or both.
(3) If such a subpoena is directed to any member, investigator, employee, or other agent or representative of the Board, including experts retained by the Board for purposes of the particular case, production of documentary evidence from the Board or investigative file of the applicant or licensee and the taking of testimony at the hearing from such person or persons shall be governed by applicable provisions in the Pharmacy Practice Act, and by O.C.G.A. §§ 16-13-60, 26-4-28, 26-4-28.1, and 26-4-60.
(3) The party requesting the issuance of the subpoena shall be responsible for serving the same and paying the cost of securing the attendance of witnesses, in the same manner as prescribed by law in civil cases in superior court.

480-44-.01 Taking of Testimony by Deposition
(1) At anytime during the course of the proceeding, the Board or its designee may, in his discretion, permit the testimony of a witness to be taken by deposition. Application to take testimony by deposition shall be made in writing and shall be filed with the Executive Director of the Board and served upon all parties to the proceedings, including counsel for the Board.
(2) The application shall state the name and address of the witness, the subject matter concerning which the witness is expected to testify, the date, time and place of the proposed deposition, and the reason why the witness cannot appear and testify before the Board. The Board or its designee may, in his, her or its discretion, allow the application where the circumstances are such that the witness to be deposed cannot appear before the Board without substantial hardship to the deponent or to the parties to the case or that testimony by any other method will unduly delay expeditious completion of the proceedings. An application for the taking of testimony by deposition shall not be allowed if the deposition would result in any undue burden to another party or any undue delay of the proceedings. If the application is allowed, the Board or its designee should give notice of the taking of the testimony by deposition to all parties.

480-44-.02 Conduct of the Deposition
(1) Examination and cross-examination of the witness shall proceed as would be permitted at the hearing and under those rules of evidence applicable to proceedings conducted pursuant to the Georgia Administrative Procedure Act. The officer before whom the deposition is to be taken shall put the witness on oath and shall personally record the testimony of the witness. The testimony shall either be taken stenographically and shall be transcribed or shall be taken by video deposition. All objections

made at the time of examination to the qualifications of the officer taking the deposition, or to the manner of taking it, or to the evidence presented, or to the conduct of any party, and any other objections to the proceedings, shall be noted by the officer upon the deposition. Evidence objected to shall be taken subject to the objection.
(2) All errors and irregularities in the notice of taking testimony by deposition shall be deemed waived unless written objection thereto is served upon the Board prior to the deposition. Objections to taking testimony by depositions because of disqualification of the officer before whom it is to be taken shall be deemed waived unless made before the deposition begins or as soon thereafter as the disqualification becomes known or could be discovered with reasonable diligence.
(3) Objections to the competency of a witness are not waived by failure to make them before or during the deposition, unless the ground of the objection is one which might have been obviated or removed if presented at that time. Errors and irregularities occurring at the taking of the testimony in the manner of taking the deposition, in the form that the questions are answered, in the oath of affirmation, or in the conduct of the parties, and errors of any kind which might be obviated, removed or cured if properly presented, shall be deemed waived unless reasonable objection thereto is made at the deposition.
(4) Errors and irregularities in the manner in which the testimony is transcribed or the deposition is prepared, certified, sealed, endorsed, transmitted, filed, or otherwise dealt with by the officer taking the testimony are waived unless a motion to suppress the deposition or some part thereof is made with reasonable promptness after such defect is, or with due diligence might have been, ascertained.
(5) The transcript of the deposition or the video deposition must be certified by a court reporter in order to be accepted as evidence upon filing with the Board or its designee.

480-44-.03 Taking of Testimony by Interrogatory
Application to take testimony by interrogatory shall be made and allowed in the same manner as prescribed in Rule 480-44-.01.

480-44-.04 Taking of Testimony by Telephone
Application to take testimony by telephone shall be made and allowed in the same manner as prescribed in Rule 480-44-.01.

480-45-.01 Notice of Hearing
For a hearing held directly before the Board, the Board shall notify all parties of record of the date, time and place of the hearing in the manner as provided by law and these Rules.

480-45-.02 Conduct of the Hearing
(1) The hearing shall be conducted by the Board or an administrative law judge (ALJ) appointed by the Office of State Administrative Hearings (OSAH).
(2) Duties of the Board or its designee. The Board or its designee shall have the authority to do the following: to administer oaths and affirmations; rule upon offers of proofs; regulate the course of the hearing; set the time and place for continued hearings; fix the time for filing briefs and memoranda; dispose of motions; and reprimand or exclude from the hearing any person for any indecorous or improper conduct committed in the presence of the Board or its designee.
(3) Sworn Testimony. All testimony given at the hearing shall be under oath administered by the Board or any person designated by the Board.
(4) Order of Presentation. The State, or in a proper case a moving or complaining party, shall present its evidence or testimony first. Where there is more than one moving or complaining party, the order of presentation shall be at the discretion of the Board. After all of the evidence and testimony of the State, or the moving or complaining party, has been received, all other parties shall be allowed to present their evidence or testimony. All parties, other than the party introducing the testimony, shall be allowed to cross-examine any witness immediately after his testimony has been received. The State, or the moving or complaining party, shall be allowed to present rebuttal testimony or evidence if it so desires.

480-46-.01 Consolidation
The Board or its designee upon its own motion, or upon motion by a party or other person joined in the proceeding, may order proceedings involving a common question of law or fact to be consolidated for hearing on any or all of the matters at issue in such proceedings.

480-47-.01 Briefs
Briefs may be filed by a party or any interested person either before or during the course of the hearing, or within such time thereafter as the Board or its designee shall designate. Failure to file a brief shall in no way prejudice the rights of any party.

480-47-.02 Filing of Documents Subsequent to Hearing
(1) Upon request, the Board or its designee may, for good cause shown, allow the parties to file evidentiary documents of any kind, or exhibits, at a time subsequent to the completion of the hearing, such time to be determined by the Board or its designee. If a request for such subsequent filing is granted, the requesting party shall, on or before the date set for filing, send copies of all documents or exhibits which are the subject of the request to all other parties.
(2) Prior to the admission into evidence of any documents or exhibits filed subsequent to the hearing, the opposing party shall have ten (10) days from the date of service of copies of such proposed documents or exhibits to file any objections to the admission of such evidence.

480-47-.03 Motion to Reopen Hearing
A party may, at any time prior to the rendering of a final decision by the Board, move that the hearing be reopened for the purpose of receiving new evidence. Such motions shall be filed in accordance with the provisions of Rule 480-40-.01 and shall be granted only for good cause shown. The Board shall notify all parties of its action upon the motion. Notwithstanding the above, the Board may at any time prior to the rendering of a decision, reopen the hearing on its own motion.

480-47-.04 Review of Initial Decision
(1) Either the responding party or the Board may seek review of the initial decision of the administrative law judge (ALJ) pursuant to O.C.G.A. §§ 50-13-17(a), 50-13-41(d). If the responding party files a timely motion for review of the initial decision of the ALJ, the responding party may include therein a statement of the reasons for seeking review and alleged errors made by the ALJ in the initial decision. If the Board files a timely order for review of the initial decision on its own motion, it may include in its order the issues to be considered by the Board at the review hearing.
(2) Upon the filing of a timely motion by the responding party seeking review of the initial decision of the ALJ, or upon the filing of a timely order by the Board for review of an initial decision on its own motion, notice of the date and time for the review shall be served on the responding party or counsel for the responding party and counsel for the Board.
(3) The Board may appoint a hearing officer for review, who shall preside over the review proceedings and control the conduct of the review hearing. In acting as the presiding officer, the hearing officer for review shall rule on all procedural and evidentiary questions that arise during the course of the review. At the direction of the Board, the hearing officer for review shall draft the final decision for the Board.
(4) On review, the Board shall have all the powers it would have in making the initial decision, and in its discretion, shall have the power to take additional testimony or remand the case to the ALJ for such purpose, as provided in the Administrative Procedure Act, O.C.G.A. § 50-13-17 and in accordance with this Rule. Motions, including motions to present additional evidence, shall be filed in accordance with 480-40-.01 and 480-47-.03 and shall be ruled upon within the time period set by the Board but not to exceed thirty (30) days.
(a) Motions to present additional evidence or to remand the case to the ALJ for such purpose shall be granted only if the additional evidence is material, and there was good cause for failing to present such evidence before the ALJ. All motions, including motions for the presentation of additional evidence, shall be ruled on by the Board, prior to oral arguments during the review hearing.

(5) Oral argument up to 30 minutes per side is permitted in the review hearing. Additional time for argument must be requested in writing and docketed at least fourteen (14) days before the date set for the review hearing.
(6) Once the review hearing is concluded, the Board shall deliberate as to the final decision. Neither the hearing officer for review nor the parties nor their counsel shall be present during or participate in the deliberations or voting on the final decision. Provided, however, that during the course of the deliberations the Board may seek or obtain legal advice of its counsel or make an inquiry on the record concerning either procedure or the merits of the case in the presence of all parties.
(a) At the conclusion of the deliberations, the vote and decision of the Board shall be announced in open session, unless the sanction imposed by the decision is made confidential by statute, in which case it shall be announced *in camera* to the responding party and counsel for the parties. The Board may take the matter under advisement and continue the deliberations until a date certain if deemed necessary due to the Board's agenda or the complexity of the issues.

480-47-.05 Rehearing
A responding party may file a motion for rehearing of a final decision of the Board within ten (10) days after the date of actual service of such final decision on the responding party or responding party's counsel. Such motion shall be in accordance with Rule 480-40-.01 and, in addition, shall include a statement of all matters alleged to have been erroneously decided and, if applicable, a statement as to any newly discovered matters or circumstances that have arisen subsequent to the final decision. The filing of said motion shall not operate as a stay of the final decision of the Board unless so ordered by the Board.

480-47-.06 Appeals of Final Decisions
All appeals shall be filed in accordance with the Georgia Administrative Procedure Act and must be filed in the Superior Court of Fulton County or superior court of the county of the residence of the petitioner.

Bill Prather seconded and the Board voted unanimously in favor of the motion. The Board will consider adopting the above mentioned rules at its May 14, 2014 meeting.

Laird Miller made a motion to post Rule 480-11-.02 Compounded Drug Preparations as amended. Chris Jones seconded and the Board voted unanimously in favor of the motion.

480-11-.02 Compounded Drug Preparations
(1) Compounded drug preparations –Pharmacist/Patient/Prescriber Relationship.
(a) Based on the existence of a pharmacist/patient/prescriber relationship and the presentation of a valid prescription drug order or in anticipation of a prescription drug order based on routine, regularly observed prescribing patterns, pharmacists may compound, for an individual patient, drug preparations that are not commercially available in the marketplace or commercially available in the place as outlined by the restrictions under 12(b). Dispensing of pharmaceutical products shall be consistent with the provisions of O.C.G.A. T. 16, Ch. 13 and T. 26, Ch. 4 relating to the issuance of prescriptions and the dispensing of drugs.
(b) Pharmacists shall receive, store, or use pharmaceuticals that have been ~~made in a FDA-approved~~ manufactured or repackaged in a FDA-registered facility. Pharmacists shall also receive, store, or use pharmaceuticals in compounding ~~prescriptions~~ preparations that meet official compendia requirements. If neither of these requirements can be met, pharmacists shall use their professional judgment to procure alternatives.
(c) Pharmacists may compound pharmaceuticals prior to receiving a valid prescription drug order based on a history of receiving valid prescription drug orders within an established pharmacist/patient/prescriber relationship, and provided that they maintain the prescriptions on file for all such preparations compounded at the pharmacy. ~~Pharmaceuticals~~ Preparations compounded in

anticipation of a valid prescription drug order shall be properly labeled to include the name of the compounded pharmaceutical, date of compounding, and beyond-use date. The distribution of compounded ~~products~~ preparations, for office use by a practitioner, shall not exceed 5% of production of compounded ~~product~~ preparation in a calendar year by that pharmacy. Amounts produced greater than 5% shall be considered manufacturing and will require separate licensure as a manufacturer. Pharmacists must maintain a separate compounding log for each ~~product~~ compounded preparation that includes the quantity and amount of each ~~product~~ pharmaceutical that is compounded. Pharmacists shall label all compounded ~~pharmaceutical products~~ preparations that are dispensed pursuant to a prescription in accordance with the provisions of O.C.G.A. T. 16, Ch. 13 and O.C.G.A. T. 26, Chs. 3 and 4, and Board rules and regulations, and shall include on the labeling an appropriate beyond-use date as determined by the pharmacist in compliance with USP-NF standards for pharmacy compounding.

(e) All ~~pharmaceutical products~~ compounded preparations labeled in accordance with Board rules and regulations regarding pharmaceutical compounding shall be deemed to meet the labeling requirements of O.C.G.A. T. 16, Ch. 13, and T. 26, Chs. 3 and 4.

(2) Compounded drug preparations – Pharmacist for Distribution to Practitioner

(a) Only a pharmacy licensed or registered by the Board may distribute compounded ~~products~~ preparations to practitioners licensed in this state for administration to their patients in the course of their professional practice, either personally or by an authorized person under their direct and immediate supervision.

(b) A practitioner shall make a request to the pharmacy for a compounded ~~pharmaceutical~~ preparation in the same manner as ordering ~~pharmaceuticals~~ products from a wholesale pharmaceutical distributor or manufacturer and not by using a prescription drug order.

(c) A pharmacy receiving an order from a practitioner for a compounded ~~pharmaceutical~~ preparation shall maintain such order with its compounding ~~rules~~ records as required in Rule 480-11-.08 and other rules and regulations of the Board.

(d) Pharmacists shall label all compounded ~~pharmaceutical products~~ preparations distributed to practitioners for administration to their patients with the following:

1. “By purchase order, Not by prescription”,
2. “For Office Use Administration Only – Not for resale”,
3. The name of the active ingredients and strengths contained in the compounded ~~pharmaceutical~~ preparation,
4. The lot number or identification of the compounded ~~pharmaceutical~~ preparation,
5. The pharmacy’s name, address and telephone number,
6. The initials of the pharmacist verifying the finished ~~product~~ compounded preparation and the date verified,
7. The quantity, amount, size, or weight of the compounded ~~pharmaceutical~~ preparation in the container,
8. An appropriate beyond-use (expiration) date of the compounded ~~pharmaceutical~~ preparation as determined by the pharmacist in compliance with Board rule and USP-NF standards for pharmacy compounding, and
9. Appropriate ancillary instructions such as storage instructions or cautionary statements, and where appropriate, hazardous drug warning labels.

(e) Pharmacists shall enter into a written agreement with a practitioner for the practitioner’s use of the compounded ~~pharmaceutical~~ preparation before providing any compounded ~~pharmaceutical~~ preparation to the practitioner. The written agreement shall provide the following information:

1. The name and address of the practitioner, license number and contact information.
2. An agreement by the practitioner that the compounded ~~pharmaceutical~~ preparation may only be administered to the patient and may not be dispensed to the patient or sold to any other person or entity.
3. An agreement by the practitioner to include on the patient’s chart, or medication administration record the lot number and beyond-use date of the compounded ~~pharmaceutical~~ preparation administered to the patient.
4. The procedures for a patient to report an adverse reaction or to submit a complaint about a compounded ~~pharmaceutical~~ preparation.

5. The procedure to be used when the pharmacy has to recall a batch of compounded ~~pharmaceuticals~~ preparation.
(f) When pharmacists are compounding sterile ~~pharmaceuticals~~ preparations to be provided to practitioners for use in patient care or when pharmacists are altering or repackaging such ~~pharmaceuticals~~ products for practitioners to use in patient care in the practitioner's office, the sterile compounding shall be conducted as allowed by applicable federal law and Board rules and shall be in compliance with USP-NF standards for sterile compounding.
(g) Sterile compounded ~~pharmaceuticals~~ preparations may be dispensed to practitioners in quantities no more than 100 individual dosage containers and must have a beyond-use date no ~~less~~ more than one week
(h) Pharmacist may not compound Schedule II, III, IV or V controlled substances, as defined in Article 2 of Chapter 13 of Title 16 without a patient specific prescription drug order.
(i) Prior to any pharmacy engaging in the practice of compounding ~~pharmaceuticals~~ preparations for use in the practitioner's office, the pharmacy must notify the Georgia Drugs and Narcotic Agency ("GDNA") of its practice, and must maintain on file the written acknowledgement of receipt of the notice from GDNA.
(j) Nothing in this paragraph shall be construed to apply to pharmacies owned or operated by institutions or to pharmacists or practitioners employed by an institution or its affiliated entities; provided, however, pharmacies owned or operated by institutions and pharmacists and practitioners within or employed by institutions or affiliated entities shall remain subject to the other rules and regulations of the Board governing the compounding of pharmaceuticals.
(3) Pharmacists must maintain documentation of proof that the beyond-use date on compounded pharmaceuticals is valid.
(4) Pharmacists shall personally perform or personally supervise the compounding process, which shall include a final verification check for accuracy and conformity to the formula of the product being prepared, correct ingredients and calculations, accurate and precise measurements, appropriate conditions and procedures, and appearance of the final product.
(5) Pharmacists shall ensure compliance with USP-NF standards for both sterile and non-sterile compounding.
(6) Pharmacists may use prescription bulk substances in compounding when such bulk substances:
(a) Comply with the standards of an applicable USP-NF monograph, if such monograph exists, including the testing requirements~~, and the Health Insurance Portability and Accountability Act of 1996 (Pub. L. No. 104-91)~~ and the Board rules on pharmaceutical compounding; or are substances that are components of pharmaceuticals approved by the FDA for use in the United States; or otherwise approved by the FDA;
(b) Are manufactured by an establishment that is registered by the FDA; and
(c) Are distributed by a wholesale distributor licensed by the Board and ~~are distributed by a supplier approved~~ registered by the FDA to distribute bulk substances if the pharmacist can establish purity and safety-by reasonable means, such as lot analysis, manufacturer reputation, or reliability of the source.
(7) Pharmacists shall maintain records of all compounded pharmaceutical products. Pharmacist shall maintain a complete compounding formula listing all procedures, necessary equipment, necessary environmental considerations, and other factors in detail when such instructions are necessary to replicate a compounded product or where the compounding is difficult or complex and must be done by a certain process in order to ensure the integrity of the finished product.
(8) Pharmacists engaged in the compounding of pharmaceuticals shall operate in conformance with ~~USP 795 and applicable state laws regarding the practice of pharmacy. (2) If low or , medium risk preparations are being compounded, they must be compounded in accordance with USP 795 and applicable laws and rules. If high risk sterile preparations are being compounded, they must be in accordance with USP 797 and~~ Georgia laws and regulations. Non-sterile compounded preparations shall be subject to USP 795. All sterile compounded preparations shall be subject to USP 797.
(9) Radiopharmaceuticals. If radiopharmaceuticals are being compounded, conditions set forth in the Board's rules for nuclear pharmacists and pharmacies must be followed.

(10) Special precaution preparations. If drug preparations with special precautions for contamination are involved in a compounding operation, appropriate measures, including either the dedication of equipment for such operations or the meticulous cleaning of contaminated equipment prior to its return to inventory, must be utilized in order to prevent cross-contamination.
(11) Cytotoxic drugs. In addition to the minimum requirements for a pharmacy established by rules of the Board, the following requirements are necessary for those pharmacies that prepare cytotoxic drugs to insure the protection of the personnel involved.
(a) All cytotoxic drugs should be compounded in a vertical flow, Class II, biological safety cabinet or an appropriate barrier isolator. Other preparations should not be compounded in this cabinet.
(b) Personnel compounding cytotoxic drugs shall wear protective apparel as outlined in the National Institute of Occupation Hazards (NIOSH.) in addition to appropriate compounding attire as described in USP 797.
(c) Appropriate safety and containment techniques for compounding cytotoxic drugs shall be used in conjunction with the aseptic techniques required for preparing sterile preparations.
(d) Disposal of cytotoxic waste shall comply with all applicable local, state, and federal requirements.
(e) Written procedures for handling both major and minor spills of cytotoxic agents must be developed and must be included in the policy and procedure manual.
(f) Prepared doses of cytotoxic drugs must be dispensed, labeled with proper precautions inside and outside, and delivered in a manner to minimize the risk of accidental rupture of the primary container.
(g) Disposal of cytotoxic and/or hazardous wastes. The pharmacist-in-charge is responsible for assuring that there is a system for the disposal of cytotoxic and/or infectious waste in a manner so as not to endanger the public health.
(12) Pharmacists shall not engage in the following:
(a) The compounding for human use of a pharmaceutical product that has been withdrawn or removed from the market by the FDA because such drug product or a component of such drug product has been found to be unsafe.
(b) The compounding of any pharmaceutical products that are essentially copies of commercially available pharmaceutical products. However, this prohibition shall not include:
1. The compounding of any commercially available product when there is a change in the product ordered by the prescriber for an individual patient,
2. The compounding of a commercially available manufactured pharmaceutical during times when the product is not available from the manufacturer or wholesale distributor,
3. The compounding of a commercially manufactured pharmaceutical ~~whose manufacturer has notified the FDA that the pharmaceutical is unavailable due to a current drug shortage~~ that appears on the drug shortages list, or
~~4. The compounding of a commercially manufactured drug when the prescriber has indicated in the oral or written prescription for an individual patient that there is an emergent need for a drug that is not readily available within the time medically necessary, or~~
~~5~~4. The mixing of two or more commercially available products of which the end product is a commercially available product.
(13) Practitioners who may lawfully compound pharmaceuticals for administering or dispensing to their own patients pursuant to O.C.G.A. Section 26-4-130 shall comply with all the provisions of this rule and other applicable Board laws, rules and regulations.

A motion was made by Jim Bracewell, seconded by Chris Jones, and the Board voted that the formulation and adoption of these amendments do not impose excessive regulatory cost on any licensee and any cost to comply with the proposed rules cannot be reduced by a less expensive alternative that fully accomplishes the objectives of the relevant code sections.

In the same motion, the Board voted that it is not legal or feasible to meet the objectives of the relevant code sections to adopt or implement differing actions for businesses as listed at O.C.G.A§ 50-13-9

4(a)(3)(A), (B), (C) and (D). The formulation and adoption of these rules will impact every licensee in the same manner and each licensee is independently licensed, owned and operated and dominant in the field of pharmacy.

Bill Prather made a motion and Jim Bracewell seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h)(2) and §43-1-2(k) to deliberate and to receive information on applications, investigative reports and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Al McConnell, Laird Miller, Jim Bracewell, Mike Faulk, Chris Jones, Tony Moye, Bill Prather and Bob Warnock.

Executive Session

Miscellaneous

The Board received advice from Ms. Wray regarding the subject of licensed respiratory therapists on staff.

No votes were taken in Executive Session. Chairperson McConnell declared the meeting back in Open Session.

Open Session

Mr. Prather commented on the status of proposed Rule 480-38-.02 Conditions for Use of Delivery by Mail. Mr. Prather stated that this is a complicated new rule and that the job of the Board is to protect the citizens of Georgia. He further stated that the Board is still in the process of working on the proposed rule.

Appearance

Appearance by WorkingBuildings Companies: Michael Weiss and Kurt Last spoke to the Board on how they may be able to help with contract compliance issues. Mr. Last explained that they are finding a lot of misunderstanding amongst pharmacies on engineering controls. He stated that what is happening now is the FDA is reinspecting pharmacies and is finding remarkable engineering control mistakes. Mr. Last wanted to make the Board aware that this is happening nationally and stated that they are available as a resource.

Chairperson McConnell asked Mr. Weiss if WorkingBuildings was working with anyone currently. Mr. Weiss responded that WorkingBuildings does have private clients they work with and are bound by confidentiality agreements regarding client names, but they do work with Emory, UGA, etc.

Mr. Miller asked Mr. Weiss and Mr. Last if WorkingBuildings works with small companies or independent pharmacies or are they more interested in pharmacies in an institution-like setting. Mr. Last responded that they have been called into smaller compounds once the facility has been shut down. Mr. Weiss added that they do receive calls on a constant basis from "mom and pop" pharmacies.
Mr. Prather asked if Mr. Weiss and Mr. Last could share what other states have done to try to mitigate the circumstances that have caused deaths. Mr. Last responded that most are going after false prescriptions.

Mr. Miller asked if there was a national database to show who was in compliance. Mr. Last responded that there is a new classification that the FDA is regulating. He further explained that there is an online database that tells if a failed inspection or any negative enforcement action has occurred. Chairperson McConnell thanked Mr. Weiss and Mr. Last for their time.

Petition for Rule Waiver – Carolyn Wilson

Jim Bracewell made a motion to grant the rule waiver petition. Chris Jones seconded and the Board voted unanimously in favor of the motion.

Bill Prather made a motion and Laird Miller seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h)(2) and §43-1-2(k) to deliberate and to receive information on applications, investigative reports and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Al McConnell, Laird Miller, Jim Bracewell, Mike Faulk, Chris Jones, Tony Moye, Bill Prather and Bob Warnock.

Executive Session

Georgia Drugs and Narcotics Agency – Rick Allen

Discussed HB744 and HB885.

Cognizant's Report – Laird Miller

- GDNA Case #A-30746
- GDNA Case #A-30747
- GDNA Case #A13-60
- GDNA Case #A13-59
- GDNA Case #B30916A
- GDNA Case #B30916B
- GDNA Case #B30916C
- GDNA Case #T-30964
- GDNA Case #T13-70
- GDNA Case #T-31032
- GDNA Case #T-30962
- GDNA Case #B-30661
- GDNA Case #B-30897
- GDNA Case #A-31029
- GDNA Case #B-30940
- GDNA Case #B-31010
- GDNA Case #A-30956
- GDNA Case #A-31005
- GDNA Case #B-31011
- GDNA Case #A-31004

Executive Director's Report – Tanja Battle

June Examination: Eric Lacefield, Deputy Executive Director, discussed the upcoming June examination with the Board.

- T.D.
- R.P.D.

Applications

- T.L.B.
- G.S.P.
- A.C.L.
- D.D.B.
- K.S.Y.

- J.B.
- B.K.R.
- E.N.S.
- Q.L.B.
- S.N.H.
- N.D.S.
- R.A.
- H.L.J.
- O.F.O.
- A.J.A.
- C.J.B.
- D.H.S.
- K.D.D.
- W.S.S.
- K.L.A.
- B.B.P.

Correspondences/Requests

- D.W.J.
- K.A.W.
- F.R.H.
- J.L.J.
- C.B.
- B.M.T.
- S.S.D.
- S.C.S.A.C.
- O.M.C.
- M.B.B.
- A.B.R.
- Y.T.H.
- M.T.H.
- R.U.K.
- A.F.D.
- C.G.I.

No votes were taken in Executive Session. Chairperson McConnell declared the meeting back in Open Session.

Open Session

Chris Jones made a motion to approve all recommendations based on deliberations in Executive Session as follows:

Appearance

- L.D.S. Overturn denial and approve for registration pending receipt of additional information

Attorney General's Report – Janet Wray

Ms. Wray presented the following consent orders for acceptance:

- C.E.C. Private Consent Order accepted
- C.V.S. Private Consent Order accepted
- C.V.S. Private Consent Order accepted
- K.D. Private Consent Order accepted
- Medisca Inc. #3095 Public Consent Order accepted
- Medisca Inc. #2778 Public Consent Order accepted
- Medisca Inc. #1086 Public Consent Order accepted
- Christopher A. Parker Public Consent Order accepted
- P. Private Consent Order accepted
- Superior Medical Supply Inc. Public Consent Order accepted
- R.E.J. Public Consent Order to be accepted and signed with express permission upon receipt of the original.

Ms. Wray presented the following Voluntary Surrender for acceptance:

- A.D.S. Voluntary Surrender accepted

Ms. Wray discussed the following cases:

- M.P.L. Close with no action and renew license
- T.C. Close with no action
- D.K. No action taken

Appearances

- K.W.A. Approved with private consent order
- R.U.K. Denial upheld
- P.A.C. Denial upheld

Miscellaneous

The Board received advice from Ms. Wray regarding the subject of licensed respiratory therapists on staff. No action taken.

Georgia Drugs and Narcotics Agency – Rick Allen

Discussed HB744 and HB885. No action taken.

Cognizant's Report – Laird Miller

- GDNA Case #A-30746 Close with Letter of Concern
- GDNA Case #A-30747 Close with Letter of Concern
- GDNA Case #A13-60 Refer to the Attorney General's office for discipline
- GDNA Case #A13-59 Refer to the Attorney General's office for discipline
- GDNA Case #B30916A Refer to the Attorney General's office for discipline
- GDNA Case #B30916B Refer to the Attorney General's office for discipline
- GDNA Case #B30916C Refer to the Attorney General's office for discipline
- GDNA Case #T-30964 Accept Voluntary Surrender
- GDNA Case #T13-70 Accept Voluntary Surrender
- GDNA Case #T-31032 Accept Voluntary Surrender
- GDNA Case #T-30962 Accept Voluntary Surrender
- GDNA Case #B-30661 Close with Letter of Concern
- GDNA Case #B-30897 Refer to the Attorney General's office for discipline
- GDNA Case #A-31029 Close with no action

- GDNA Case #B-30940 Close with no action
- GDNA Case #B-31010 Refer to the Attorney General's office for discipline
- GDNA Case #A-30956 Refer to the Attorney General's office for discipline
- GDNA Case #A-31005 Refer to the Attorney General's office for discipline
- GDNA Case #B-31011 Close with Letter of Concern
- GDNA Case #A-31004 Close with Letter of Concern

Executive Director's Report – Tanja Battle

- June Examination: Eric Lacefield, Deputy Executive Director, discussed the upcoming June examination with the Board. No action taken.
- T.D. Correspondence Respond to licensee as directed
- R.P.D. Correspondence requesting guidance Respond to licensee as directed

Applications

• T.L.B.	Pharmacy Technician	Overturned denial and approved registration
• G.S.P.	Pharmacy Technician	Table pending receipt of additional information
• Alexander C. Love	Pharmacy Technician	Approved registration
• D.D.B.	Pharmacy Technician	Table pending receipt of additional information
• K.S.Y.	Pharmacy Technician	Denied registration
• J.B.	Pharmacy Technician	Table pending receipt of additional information
• B.K.R.	Pharmacy Technician	Table pending receipt of additional information
• E.N.S.	Pharmacy Technician	Denied registration
• Q.L.B.	Pharmacy Technician	Table pending receipt of additional information
• Shequana N. Harper	Pharmacy Technician	Approved registration
• Nicole D. Sivels	Pharmacy Technician	Approved registration
• Reshma Amin	Pharmacy Technician	Approved for renewal
• Hannah L. Jones	Pharmacy Technician	Approved for renewal
• O.F.O.	Pharmacist Renewal	Refer to the Attorney General's office for discipline
• Amirio J. Armour	Pharmacist Reciprocity	Approved application
• Christopher J. Becker	Pharmacist Reciprocity	Approved application
• Denis H. St. Pierre	Pharmacist Reciprocity	Approved application
• K.D.D.	Pharmacist Reciprocity	Denied application
• William S. Sandlin	Pharmacist Reciprocity	Approved application
• K.L.A.	Pharmacist Intern	Denied application
• B&B Pharmaceuticals	Wholesaler Pharmacy	Approved application

Correspondences/Requests

• D.W.J.	Appearance Request	Approved request
• K.A.W.	Request to term probation	Schedule for an appearance with the Board
• F.R.H.	Remote order entry	Denied
• J.L.J.	Refund request	Approved request
• C.B.	Correspondence	Viewed as informational
• B.M.T.	Request to lift PIC restriction	Approved request

• S.S.D.	Request for approval of CE course for consent order	Approved request
• S.C.S.A.C.	Dispensing procedure	Approved procedure
• O.M.C.	Remote order entry	Approved
• M.B.B.	Request to lift weekly Meeting requirement	Table pending receipt of additional information
• A.B.R.	Request to terminate probation	Denied request
• Y.T.H.	Request to sit for MPJE	Approved request pending additional information
• M.T.H.	Extension request	Approved request
• R.U.K.	Request for Board to consider a modification of Board policy No. 3A	Denied request
• A.F.D.	Correspondence	Viewed as informational
• C.G.I.	Correspondence	Viewed as informational

Laird Miller seconded and the Board voted in favor of the motion.

The next scheduled meeting of the Georgia Board of Pharmacy is scheduled for Wednesday, April 16, 2014, at 9:00 a.m. at Department of Community Health's office located at 2 Peachtree Street, N.W., 36th Floor, Atlanta, GA 30303.

The Board meeting adjourned at 4:24 p.m.

Minutes recorded by Brandi P. Howell, Business Operations Specialist
Minutes edited by Tanja D. Battle, Executive Director